Utilization and impact of a postmastectomy radiation boost for invasive breast cancer

Jyoti Mayadev, Kari Fish, Richard K Valicenti, Dee West, Allen Chen, Steven Martinez, Theodore Phillips

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Additional radiation following postmastectomy radiation (PMRT) has an undefined benefit. We investigate those likely to be selected for a chest wall boost (CWB) and its effect on breast cancer survival (BCS) and overall survival (OS). Methods and materials: A total of 4747 women diagnosed from 2005 to 2009 were treated with PMRT identified from the California Cancer Registry (CCR); 2686 (57%) received a CWB. Univariate and multivariate analyses compared those receiving and not receiving a CWB for BCS and OS. Results: With a median follow-up of 43.6 months, patients likely to receive a CWB were stage III (. P ≤ .001), grade 3/4 (. P = .03), positive nodes (. P = .04), HER 2. + (. P =. .02). CWB was not related to BCS in the univariate (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.82-1.21), multivariate (HR, 1.04; 95% CI, 0.86 -1.26) analyses, and was not related OS for the univariate (HR, 0.92; 95% CI, 0.78-1.10), multivariate (HR, 0.95; 95% CI, 0.80-1.13) analyses. However, in multivariate analysis, patients not receiving chemotherapy who had a CWB had better BCS (HR, 1.77; 95% CI, 1.11-2.83). Conclusions: The majority of patients were treated with a CWB. We found no difference in BCS or OS with the addition of a CWB.

Original languageEnglish (US)
Pages (from-to)E269-E278
JournalPractical Radiation Oncology
Volume4
Issue number6
DOIs
StatePublished - Nov 1 2014

Fingerprint

Thoracic Wall
Radiation
Breast Neoplasms
Survival
Confidence Intervals
Multivariate Analysis
Registries
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Utilization and impact of a postmastectomy radiation boost for invasive breast cancer. / Mayadev, Jyoti; Fish, Kari; Valicenti, Richard K; West, Dee; Chen, Allen; Martinez, Steven; Phillips, Theodore.

In: Practical Radiation Oncology, Vol. 4, No. 6, 01.11.2014, p. E269-E278.

Research output: Contribution to journalArticle

Mayadev, Jyoti ; Fish, Kari ; Valicenti, Richard K ; West, Dee ; Chen, Allen ; Martinez, Steven ; Phillips, Theodore. / Utilization and impact of a postmastectomy radiation boost for invasive breast cancer. In: Practical Radiation Oncology. 2014 ; Vol. 4, No. 6. pp. E269-E278.
@article{8d84583c181549f6b3b3ada20cc8ae5a,
title = "Utilization and impact of a postmastectomy radiation boost for invasive breast cancer",
abstract = "Additional radiation following postmastectomy radiation (PMRT) has an undefined benefit. We investigate those likely to be selected for a chest wall boost (CWB) and its effect on breast cancer survival (BCS) and overall survival (OS). Methods and materials: A total of 4747 women diagnosed from 2005 to 2009 were treated with PMRT identified from the California Cancer Registry (CCR); 2686 (57{\%}) received a CWB. Univariate and multivariate analyses compared those receiving and not receiving a CWB for BCS and OS. Results: With a median follow-up of 43.6 months, patients likely to receive a CWB were stage III (. P ≤ .001), grade 3/4 (. P = .03), positive nodes (. P = .04), HER 2. + (. P =. .02). CWB was not related to BCS in the univariate (hazard ratio [HR], 1.00; 95{\%} confidence interval [CI], 0.82-1.21), multivariate (HR, 1.04; 95{\%} CI, 0.86 -1.26) analyses, and was not related OS for the univariate (HR, 0.92; 95{\%} CI, 0.78-1.10), multivariate (HR, 0.95; 95{\%} CI, 0.80-1.13) analyses. However, in multivariate analysis, patients not receiving chemotherapy who had a CWB had better BCS (HR, 1.77; 95{\%} CI, 1.11-2.83). Conclusions: The majority of patients were treated with a CWB. We found no difference in BCS or OS with the addition of a CWB.",
author = "Jyoti Mayadev and Kari Fish and Valicenti, {Richard K} and Dee West and Allen Chen and Steven Martinez and Theodore Phillips",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.prro.2014.05.006",
language = "English (US)",
volume = "4",
pages = "E269--E278",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Utilization and impact of a postmastectomy radiation boost for invasive breast cancer

AU - Mayadev, Jyoti

AU - Fish, Kari

AU - Valicenti, Richard K

AU - West, Dee

AU - Chen, Allen

AU - Martinez, Steven

AU - Phillips, Theodore

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Additional radiation following postmastectomy radiation (PMRT) has an undefined benefit. We investigate those likely to be selected for a chest wall boost (CWB) and its effect on breast cancer survival (BCS) and overall survival (OS). Methods and materials: A total of 4747 women diagnosed from 2005 to 2009 were treated with PMRT identified from the California Cancer Registry (CCR); 2686 (57%) received a CWB. Univariate and multivariate analyses compared those receiving and not receiving a CWB for BCS and OS. Results: With a median follow-up of 43.6 months, patients likely to receive a CWB were stage III (. P ≤ .001), grade 3/4 (. P = .03), positive nodes (. P = .04), HER 2. + (. P =. .02). CWB was not related to BCS in the univariate (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.82-1.21), multivariate (HR, 1.04; 95% CI, 0.86 -1.26) analyses, and was not related OS for the univariate (HR, 0.92; 95% CI, 0.78-1.10), multivariate (HR, 0.95; 95% CI, 0.80-1.13) analyses. However, in multivariate analysis, patients not receiving chemotherapy who had a CWB had better BCS (HR, 1.77; 95% CI, 1.11-2.83). Conclusions: The majority of patients were treated with a CWB. We found no difference in BCS or OS with the addition of a CWB.

AB - Additional radiation following postmastectomy radiation (PMRT) has an undefined benefit. We investigate those likely to be selected for a chest wall boost (CWB) and its effect on breast cancer survival (BCS) and overall survival (OS). Methods and materials: A total of 4747 women diagnosed from 2005 to 2009 were treated with PMRT identified from the California Cancer Registry (CCR); 2686 (57%) received a CWB. Univariate and multivariate analyses compared those receiving and not receiving a CWB for BCS and OS. Results: With a median follow-up of 43.6 months, patients likely to receive a CWB were stage III (. P ≤ .001), grade 3/4 (. P = .03), positive nodes (. P = .04), HER 2. + (. P =. .02). CWB was not related to BCS in the univariate (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.82-1.21), multivariate (HR, 1.04; 95% CI, 0.86 -1.26) analyses, and was not related OS for the univariate (HR, 0.92; 95% CI, 0.78-1.10), multivariate (HR, 0.95; 95% CI, 0.80-1.13) analyses. However, in multivariate analysis, patients not receiving chemotherapy who had a CWB had better BCS (HR, 1.77; 95% CI, 1.11-2.83). Conclusions: The majority of patients were treated with a CWB. We found no difference in BCS or OS with the addition of a CWB.

UR - http://www.scopus.com/inward/record.url?scp=84912528842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912528842&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2014.05.006

DO - 10.1016/j.prro.2014.05.006

M3 - Article

C2 - 25407878

AN - SCOPUS:84912528842

VL - 4

SP - E269-E278

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

IS - 6

ER -